Eruzun H. Sclerosing cholangitis associated with dabrafenib–trametinib therapy: BRAF/MEK inhibitors should be considered. JGLD [Internet]. 2026 Mar. 27 [cited 2026 Jul. 18];35(1):136-7. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/6698